Conventional type 1 DCs (cDC1) elicit anti-tumor immunity, thus, tumor cells may limit antitumor immune responses by inhibiting cDC1 recruitment at an early stage [50, 51]. The gene discussed is MPPE1; the disease is neoplasm.